The Massachusetts-based company has claimed the year’s largest fundraise so far and secured a powerhouse R&D partner in Novo Nordisk to develop gene editing medicines.
https://www.pharmalive.com/wp-content/uploads/2023/04/BioSpacedollars.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-05-24 09:37:042023-05-24 09:37:04ElevateBio takes title of largest 2023 funding with $401M Series D
